{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["45"],"submitter":["Bjartell A"],"pubmed_abstract":["<h4>Background</h4>Prostate cancer has a multifaceted treatment pattern. Evidence is lacking for optimal treatment sequences for metastatic castration-resistant prostate cancer (mCRPC).<h4>Objective</h4>To increase the understanding of real-world treatment pathways and outcomes in patients with mCRPC.<h4>Design setting and participants</h4>A prospective, noninterventional, real-world analysis of 3003 patients with mCRPC in the Prostate Cancer Registry (PCR; NCT02236637) from June 14, 2013 to July 9, 2018 was conducted.<h4>Intervention</h4>Patients received first- and second-line hormonal treatment and chemotherapy as follows: abiraterone acetate plus prednisone (abiraterone)-docetaxel (ABI-DOCE), abiraterone-enzalutamide (ABI-ENZA), abiraterone-radium-223 (ABI-RAD), docetaxel-abiraterone ("],"journal":["European urology open science"],"pagination":["12-22"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9637537"],"repository":["biostudies-literature"],"pubmed_title":["Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry."],"pmcid":["PMC9637537"],"pubmed_authors":["Lukac M","Peer A","Wapenaar R","Parikh O","Chowdhury S","Smith E","Bennamoun M","Garcia Freire C","Ecke T","Kramer G","Zurawski B","Costa L","Cicin I","Bjartell A","Werbrouck P","Ljungberg B","Galli L"],"additional_accession":[]},"is_claimable":false,"name":"Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry.","description":"<h4>Background</h4>Prostate cancer has a multifaceted treatment pattern. Evidence is lacking for optimal treatment sequences for metastatic castration-resistant prostate cancer (mCRPC).<h4>Objective</h4>To increase the understanding of real-world treatment pathways and outcomes in patients with mCRPC.<h4>Design setting and participants</h4>A prospective, noninterventional, real-world analysis of 3003 patients with mCRPC in the Prostate Cancer Registry (PCR; NCT02236637) from June 14, 2013 to July 9, 2018 was conducted.<h4>Intervention</h4>Patients received first- and second-line hormonal treatment and chemotherapy as follows: abiraterone acetate plus prednisone (abiraterone)-docetaxel (ABI-DOCE), abiraterone-enzalutamide (ABI-ENZA), abiraterone-radium-223 (ABI-RAD), docetaxel-abiraterone (","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-19T23:16:02.613Z","creation":"2025-04-19T23:16:02.613Z"},"accession":"S-EPMC9637537","cross_references":{"pubmed":["36353661"],"doi":["10.1016/j.euros.2022.08.018"]}}